Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06560645
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-06
Brief Title:
A Study of PRT7732 an Oral SMARCA2 Degrader in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT7732 an Oral SMARCA2 Degrader in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 study to determine the safety tolerability pharmacokinetics pharmacodynamics and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation
Detailed Description:
This is an open-label multi-center first-in-human Phase 1 study to determine the safety tolerability pharmacokinetics pharmacodynamics and preliminary efficacy of PRT7732 an oral SMARCA degrader in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation Approximately 104 participants will be enrolled
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None